Opinion|Videos|January 9, 2025
Navigating Treatment Options: Understanding Risks and Benefits
Author(s)David Dingli, MD, PhD, Brandi Lewis
Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you help patients weigh the risks and benefits of different treatment options?
- What tools or techniques do you use to ensure patients and caregivers fully understand their choices?
This program was made possible with support from Novartis Pharmaceuticals.
Advertisement
Related to this article
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5